Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2024

Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis

Jim Werngren
Arnold Bainomugisa
Ramona Groenheit
Paolo Miotto
Christopher Coulter
Claudio Köser

Résumé

ABSTRACT Results from clinical strains and knockouts of the H37Rv and CDC1551 laboratory strains demonstrated that ndh ( Rv1854c ) is not a resistance-conferring gene for isoniazid, ethionamide, delamanid, or pretomanid in Mycobacterium tuberculosis . This difference in the susceptibility to NAD-adduct-forming drugs compared with other mycobacteria may be driven by differences in the absolute intrabacterial NADH concentration.

Dates et versions

hal-04463114 , version 1 (16-02-2024)

Identifiants

Citer

Sushil Pandey, Catherine Vilchèze, Jim Werngren, Arnold Bainomugisa, Mikael Mansjö, et al.. Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2024, 68 (1), ⟨10.1128/aac.01096-23⟩. ⟨hal-04463114⟩
19 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More